हिन्दी
English
मराठी
বাংলা
தமிழ்
മലയാളം
ગુજરાતી
తెలుగు
ಕನ್ನಡ
ଓଡ଼ିଶା
Business
Tech
World
Health
NEWS
VIDEOS
PHOTOS
Web Stories
LIVE TV
GO
Latest
India
Ahmedabad
Bengaluru
Chennai
Hyderabad
Kolkata
Mumbai
Pune
Cricket
Success Story
Entertainment
Hollywood
Music
Bollywood
Television
Regional
Movie Review
Lifestyle
Relationship
Travel
Food & Recipes
Fashion
Culture
Spirituality
Business
Economy
Markets
Companies
Real Estate
International Business
Personal Finance
Automobile
Technology
Gadgets
Gaming
Internet & Social Media
Apps
Mobiles
World
Asia
Africa
Americas
Australia-Oceania
Europe
Auto
Mobility
Viral
Diabytes
Fables of Facades
Archived Videos
Newsletter
Newsletter
Fables of Facades
Latest
India
Cricket
Success Story
Entertainment
Lifestyle
Business
World
Auto
Mobility
Viral
Fables of Facades
Archived Videos
Newsletter
Latest
India
Cricket
Success Story
Entertainment
Lifestyle
Business
World
Auto
Mobility
Viral
Fables of Facades
Archived Videos
Newsletter
Advertisement
X
News
SII
SII News
Cyrus Poonawalla
16 Jul 2023
Cyrus Poonawalla: The Son Of A Horse Breeder Who Carved His Own Path
Cyrus Poonawalla founded the Serum Institute of India (SII) in 1966, which is today the world's largest vaccine manufacturer.
COVID-19
09 Jan 2023
Covid situation in India better than elsewhere: SII CEO Adar Poonawalla
Covid-19 In India: India is in a better position to tackle the Covid crisis because of the government, healthcare workers and a common goal to tame the virus, said SII CEO Adar Poonawalla.
World Health Organization
01 Nov 2022
'XBB variant may cause new Covid-19 wave': WHO warns as Indians ditch booster
"There are over 300 subvariants of Omicron. I think the one that is concerning right now is XBB, which is a recombinant virus. We had seen some recombinant viruses earlier. It is very immune-evasive, which means it can overcome the antibodies. So slightly that we may see another wave of infections in some countries because of XBB," WHO said.
COVID-19
01 Nov 2022
People fed up of Covid-19 pandemic, no takers for booster jabs: SII CEO
"Since December 2021, we have stopped the production of the Covishield vaccine. We had a stock of a few hundred million doses at that time and of that 100 million doses had already expired," Poonawalla said.
Monkeypox
26 Jul 2022
Good news! SII in talks with Novovax to develop vaccine against monkeypox
SII is in talks with Novovax to develop a vaccine against monkeypox This has been confirmed by SII CEO Adar Poonawalla He said that SII is working with Novovax to develop a messenger RNA for monkeypox
Serum Institute of India
24 May 2022
Serum Institute planning to set up its 1st manufacturing plant in Africa
Serum Institute of India is considering setting up its first manufacturing plant in Africa World`s biggest vaccine maker looks to expand globally after its success in selling Covid-19 shots. 'It`s never been a better time to be a vaccine manufacturer,' SII CEO Adar Poonawalla said at the World Economic Forum.
COVID-19 coronavirus
05 May 2022
Covovax available for everyone above age of 12 years: SII CEO Adar Poonawalla
Adar Poonawalla clarified that the Covid-19 vaccine Covovax is available for everyone above the age of 12 years. Earlier, on Tuesday, SII CEO had informed that Covovax (Novavax) is now available for children in India.
COVID-19
03 May 2022
Fourth wave: SII slashes price of each dose of Covovax jab, check details
SII has slashed the price of each dose of Covovax The price of each dose anti-Covid jab has been slashed from Rs 900 to Rs 225 SII CEO has said that Covovax is now available for children in India
Covovax
29 Apr 2022
NTAGI approves SII's covid vaccine Covovax for 12-17 age group: Sources
The National Technical Advisory Group on Immunization (NTAGI) on Friday approved Serum Institute of India's Covid-19 vaccine Covovax for the 12-17 age group, as per ANI.
Fourth Wave
04 Apr 2022
Fourth wave of Covid-19 to hit India? Here's what SII CEO Adar Poonawalla says
Speaking to reporters on the sidelines of the ‘Alternate Fuel Conclave’, the SII CEO said the reason behind the low number of Covid-19 cases at the moment is that the country chose the right vaccine.
Novovax
23 Mar 2022
Novovax Covid-19 vaccine gets EUA nod for those aged between 12-18 yrs
According to an official statement released by Novovax, the vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by the Serum Institute of India (SII) under the brand name Covovax and is the first protein-based vaccine authorized for use in this age group in India.
SII
09 Mar 2022
SII's ‘Covovax’ gets emergency use nod for children aged above 12 years
"Novavax in global trials has demonstrated more than 90 per cent efficacy. Serum Institute of India`s brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly," SII CEO Adar Poonawala said in a tweet.
COVID-19
15 Dec 2021
'SII working to develop COVID-19 booster shot more effective against Omicron'
SII Chief Executive Officer Adar Poonawalla said COVID vaccines for children aged above 3 years will be launched in the next 6 months.
COVID-19 booster shot
02 Dec 2021
SII seeks approval for Covishield vaccine as booster dose amid Omicron scare
The Serum Institute of India is the first Indian company to seek approval for the COVID-19 booster dose. The new Omicron variant was first reported to the WHO by South Africa on November 24.
Covovax
28 Nov 2021
Covovax not approved in country of origin yet: Govt panel tells SII
The Serum Institute of India (SII) had put in an application to the Drugs Controller General of India (DCGI) in October for grant of market authorisation of Covovax for restricted use in emergency situations.
SII
21 Nov 2021
SII requests Centre to fast-track movement of increasing Covishield stock
SII has urged the Centre to fast-track movement of Covishield domestically and globally. SII can export 50 Lakh doses of Covishield under COVAX.
Novavax
19 Nov 2021
India allows export of 20 million Novavax COVID vaccine doses to Indonesia
The government has also decided to allow the export of 10 million doses of a licensed version of the AstraZeneca shot made by SII, branded Covishield, to the global vaccine-sharing programme COVAX, two sources said.
COVID-19
18 Nov 2021
Vaccine hesitancy in India greatest threat in overcoming COVID pandemic: SII
Adar Poonawalla’s family-owned company SII is preparing to resume exports to the COVAX international vaccine sharing program for the first time since April.
Covovax
21 Aug 2021
Serum Institute files for WHO Emergency Use Listing for its Covovax vaccine
Serum Institute of India has filed for WHO emergency use listing for its upcoming COVID vaccine Covovax. The WHO has accepted the application of the Pune-based pharmaceutical company. A pre-submission meeting was also held on August 10.
Serum Institute
29 Jul 2021
Seized COVID vaccine vials not Covishield: Serum Institute to Kolkata Police
Serum Institute has communicated to Kolkata Police that the seized vials with labels of Covishield vaccine in the fake vaccine case in Kolkata was not Covishield vaccine. For further examination, Kolkata Police has sent those vials to Drug Controller for chemical examination.
1134453
1
2
Loading...
Trending news
DNA Video
DNA: Were Muslims Stopped from Voting in UP By-Elections?
DNA Video
DNA: Who Did Maharashtra’s Muslims Vote For?
DNA Video
DNA: Russia-Ukraine Conflict Escalates Amid Missile Attacks
DNA Video
DNA: The Beer-Loving Buffalo Stuck in Bihar!
DNA Video
DNA: Akhilesh and the Burqa Controversy in UP Elections
DNA Video
DNA: Is the Opposition to ‘Bantenge To Katenge’ Part of a Larger Plan?
DNA Video
DNA: RSS Master Plan: From Maharashtra to UP
DNA Video
DNA: Bengal’s Waqf Property Controversy
DNA Video
DNA: Is ‘Vote Jihad’ a Reality in Maharashtra?
DNA Video
DNA: Naresh Meena Slaps Officer, Sparks Uproar in Tonk
Subscribe Now
×
Enroll for our free updates
Please enter full name.
Please enter valid email address.
https://zeenews.india.com/
Subscribe Now
Thank you
×
Cookies Settings
Reject
Accept Cookies
NEWS ON ONE CLICK